Posted by Michael Wonder on 02 Nov 2023
Phathom Pharmaceuticals announces FDA approval of Voquenza (vonoprazan) tablets for the treatment of erosive GERD and relief of heartburn associated with erosive GERD in adults
1 November 2023 - Voqeuenza met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating Voquenza in comparison to a standard-of-care proton pump inhibitor.
Phathom Pharmaceuticals announced today the US FDA has approved Voquenza (vonoprazan) 10 mg & 20 mg tablets, a novel potassium-competitive acid blocker, as a new treatment for adults for the healing of all grades of erosive oesophagitis, also known as erosive GERD (gastro-esophageal reflux disease), maintenance of healing of all grades of erosive GERD, and relief of heartburn associated with erosive GERD.
